Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed its Q3 2025 10-Q quarterly report on Oct 30, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $313M with net income of $43M.
Q3 2025 key financials · XBRL
- Revenue
- $313M
- +3.6% QoQ
- Net income
- $43M
- +138.9% QoQ
- Operating margin
- 13.7%
- Gross margin
- 73.5%
- EPS (diluted)
- $0.33
- +135.7% QoQ
Source: XBRL data from the Indivior Pharmaceuticals, Inc. (INDV) Q3 2025 10-Q on SEC EDGAR. USD.
Indivior Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No changes in cash position, operating cash flow, or capital deployment reported
- No updated guidance, outlook, or headwinds mentioned for near term
Risk Factors
- New regulatory risk from 2025 OBBBA law, potentially limiting patient eligibility and treatment access for OUD starting 2027-2028
- Material update: CMS finalized Marketplace Integrity and Affordability Regulation in June 2025, changing ACA open enrollment and premium tax credit eligibility
- Legal risk: ongoing litigation settlements requiring scheduled payments impacting cash flows in both 2024 and 2025 periods
- Operational risk: potential deprioritization or removal of innovative, higher-cost treatments from state formularies affecting near-term product access
- Financial risk: cash and investments increased to $473M from $347M; long-term borrowings decreased to $304M from $315M at Sept 30, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Indivior Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.